What nonpharmacologic measures should the nurse suggest when vomiting occurs?
Chemotherapy induced nausea and vomiting (CINV) is a common and extremely unpleasant side effect for children receiving chemotherapy. CINV can lead to complications of treatment and also cause significant emotional and physical distress, disruptions to activities of daily living and influence the quality of life of the patient. The goal of antiemetic therapy is to prevent vomiting and minimise nausea both during and after the administration of chemotherapy. The severity of nausea and vomiting can, to some degree, be predicted by the chemotherapeutic agents being delivered but there is a degree of variation between patients. Antiemetic treatments should be initiated prior to the first dose of chemotherapy for best control of nausea and vomiting, as it can often become difficult to control nausea once the child is actually vomiting. Non-pharmacological measures are also an important consideration and should be implemented in conjunction with pharmacological regimes to allow for the effective management of CINV. Show
AimThe aim of this guideline is to provide an overview of the prevention and management of chemotherapy induced nausea and vomiting in the paediatric oncology patient. Definition of terms
AssessmentAll patients receiving chemotherapy for childhood cancer or as pre conditioning for a haematopoietic stem cell transplant (HSCT) require ongoing assessment of the incidence and severity of nausea and vomiting. It is the responsibility of nursing staff to regularly assess patients for signs and symptoms of CINV and decide on subsequent methods of management in consultation with the medical team. The following assessment tools can assist in determining the incidence and severity of CINV. Results of the assessment tools should be clearly documented once per shift (more frequently if indicated) in the Electronic Medical Record. The CINV score (0 to 10) and type of scale (BARF or VAS) utilized should be recorded under the Nausea Scale assessment in the Observation flowsheet. Baxter retching faces (BARF) nausea scaleVisual Analogue Scale (VAS)
* Baxter Retching Faces Nausea Scale & Visual Analogue Scale- Baxter et al., 2011 Each of the scales establishes a score from 0 to 10
Other indications of children experiencing CINV may include
Management and principles of preventing and treating chemotherapy induced nausea and vomitingEmetic potential of chemotherapy agentsChemotherapy agents have different emetic potentials that are classified based on their risk of inducing nausea and vomiting Low Emetogenic Potential
Moderate Emetogenic Potential
Highly Emetogenic Potential
Often, combinations of moderately emetogenic agents can yield a course with high emetic potential; for example both ifosfamide and doxorubicin have moderate emetic potential yet when delivered together have high emetic potential. Other combinations of chemotherapy can, as a whole, have low emetic potential but with extra antiemetic cover required at certain times; for example high risk ALL induction is generally low emetic potential but antiemetics are usually required around daunorubicin doses. Antiemetic treatments should be decided based on the emetic potential of the prescribed course of chemotherapy, although there may be some instances where a specific child requires deviations from the guidelines. These decisions should be discussed with the child’s fellow or consultant. Once an effective antiemetic regimen has been determined for an individual child, this regimen should be used for future courses of chemotherapy as appropriate. Full list of emetic potential of individual agents here. Pharmacological prevention and management of CINVIn order for CINV prophylaxis to be effective;
Antiemetic Prophylaxis guidelineMinimal emetic potentialLow emetic potential Moderate emetic potentialHigh emetic potential
Antiemetics should be continued throughout the period of administration of chemotherapy and for at least 24 hours following completion of chemotherapy. Breakthrough CINV guidelineBreakthrough nausea and vomiting should be treated promptly. It is advised to have further antiemetics charted on the treatment plan under the Oncology tab on EMR to enable nurses to initiate breakthrough medication as required. A suggested order of escalation in the face of breakthrough nausea and vomiting is tabulated below but this should be adjusted for individual situations. Consideration should be given to the contribution of anticipatory nausea and vomiting which is likely to respond better to benzodiazepines and non-pharmacologic management. Low emetic potential Moderate emetic potential High emetic potential
Delayed CINVThis is defined as CINV occurring 1-5 days after chemotherapy and is most commonly associated with anthracyclines or platinum agents such as cisplatin or carboplatin. Regular antiemetics should be continued for at least 48 hours after completion of cisplatin and in any other course of chemotherapy where delayed CINV has occurred in the past. Consideration may be given to a second dose of aprepitant on day 3-4 of chemotherapy if this is appropriate. Ongoing dexamethasone and ondansetron may be sufficient. Antiemetic medications table
Drug Class RouteDose Considerations Ondansetron 5HTз (serotonin) receptor antagonist.
IV/PO/SL 0.15 mg/kg to amaximum 8mg 8/24 Can be given 6/24 with highly emetogenic chemotherapy Efficacy is enhanced with Dexamethasone administration Metoclopramide Dopamine receptor antagonistActs on dopaminergic receptors in the CTZ & on peripheral vagal receptors to accelerate gastric emptying In high dose may act on 5HTз receptors in the CTZ IV/PO 0.15mg/kg to a maximum of 10mg 8/24Dystonic reactions including oculogyric crises are rare but caution is advised for first exposure to drug Dexamethasone Corticosteroid
IV/PO <0.6m² : 2mg 12/24 (pre chemotherapy loading dose 4mg)0.6-1.5m² : 4mg 12/24 (pre chemotherapy loading dose 8mg) >1.5m² : 6mg 12/24 (pre chemotherapy loading dose 12mg) Can consider increasing to 8/24 if breakthrough vomiting occurs Maximum of 12 doses per course of chemotherapy Caution in patients with AML- increases risk of infection (consultant approval required) Not for use in patients where corticosteroids are part of their chemotherapy regime (B & T Cell ALL, NHL) Not for use in children having chemotherapy for CNS tumours without direct fellow or consultant approval- may impair CNS penetration of chemotherapy If using Aprepitant, halve the dose of Dexamethasone (Aprepitant doubles the AUC of Dexamethasone) Cyclizine Antihistamine IV/PO 0.5-1mg/kg to a maximum of 50mg 8/24Not for use in infants <1 yearNot a powerful antiemetic but may be used if vomiting persists despite recommended regimes Rapid IV administration can cause drowsiness and dizziness May antagonize the prokinetic effect of Metoclopramide Aprepitant Neurokinin-1
PO Single dose administered on day 1 of chemotherapyBased on BSA; 0.5-0.8m²=55mg 0.8-1.2m²=110mg >1.2m² BSA= 165mg Course can be extended in some cases if required- discuss with fellow or consultant Administer oral dose 1 hour prior to chemotherapy Aprepitant increases steroid AUC; regimens including steroid medications, should have their dosages halved when also receiving Aprepitant (check with consultant) Lorazepam Benzodiazepine SL/PO 12-16 kg=0.25mg BD16-20 kg=0.5mg BD 20-30 kg=1mg BD > 30 kg=2mg BD Useful for anticipatory nausea and vomiting Should only be administered for short courses; usually charted PRN Domperidone Dopamine antagonist PO a maximum of 10mg QID Similar action to Metoclopramide but less of a central antiemetic effectConsider use if nausea is associated with delayed gastric emptying Chlorpromazine Phenothiazine antipsychotic.Has antidopaminergic, antiadrenergic, antiserotonergic, anticholingeric and antihistaminergic effects IV 0.3-0.5mg/kg 6-8/24Minimum infusion rate- 30 minutes Rapid administration can cause hypotension and dysphoria Not for use in infants <1 year Antiemetic guideline for common chemotherapy combinations Antiemetic Traffic Light Regimen.Further considerations
Non-pharmacological management of CINVDespite the advances in pharmacological management, standard pharmacological regimes may not fully alleviate symptoms of CINV in paediatric oncology patients. Investigating the adjuvant role of non-pharmacological interventions is an important consideration of antiemetic therapy. Non-pharmacological measures should be implemented in conjunction with pharmacological regimes to allow for the effective management of CINV. The use of non-pharmacological measures may not be appropriate for each patient, interventions should be implemented according to the individual patient's needs and circumstances. Music therapy / relaxationMusic therapy and relaxation are beneficial interventions in managing CINV with minimal negative side effects. Music therapy may include a) live and active music engagement, and b) individual (recorded) music listening for refocusing and/or relaxation. These interventions are suitable for all ages, are cost effective and can be implemented in the inpatient, outpatient and home environments. The music therapist is available to assess and advise on the most suitable plan for each patient.
For children aged under 7 years, active music engagement may be more effective than passive music listening. The music therapist can advise/plan for this. See also section on Cognitive Distraction. Guided imageryEncouraging patients to focus on thoughts and images they find pleasing and relaxing will divert attention from nausea and vomiting to desirable thoughts and images.
Cognitive distractionCognitive distraction acts to counteract CINV by drawing a patient’s attention away from feelings of nausea and vomiting and focusing attention on more pleasant activities. Patients should be encouraged to participate in;
The Educational Play Therapy, Art Therapy and Music Therapy teams can assist in providing activities that promote cognitive refocussing to effectively manage CINV. MassageEducating families to perform massage during periods of chemotherapy has a positive impact on reducing levels of stress, anxiety, nausea and vomiting.
AcupressureThe acupressure technique involves the pressure applied to and then released from acupoints. Acupressure may be performed manually or with wrist pressure bands (also used for motion/travel sickness).
Manual acupressure
ConsiderationsDietary considerationsThe following suggestions may be useful to help manage nausea and vomiting;
Enteral nutrition (i.e. Nasogastric/PEG feeds)
Other considerations
Companion documentsInformation for parentsInformation for Health ProfessionalsEvidence tableSee attached document. References
Please remember to read the disclaimer. The development of this nursing guideline was coordinated by Lisa Barrow, CNE, and Chantelle Di Gregorio, CNS, of Kookaburra, and approved by the Nursing Clinical Effectiveness Committee. Updated February 2019. Which nonpharmacologic intervention is beneficial to a patient experiencing nausea and vomiting?Continue to monitor for dehydration. Teach the patient nonpharmacological interventions for nausea such as: Drink enough fluids to avoid dehydration.
What are the precautionary instructions that we can give in patients taking anti emetic?Contraindications and Precautions of Antiemetic Drugs. Do not take these medications with alcohol.. Use with caution in children and the elderly.. Women who are pregnant or nursing should not use these medications.. Use antidopaminergics with caution in patients with renal disease.. What is the recommended treatment of nausea and vomiting when caring for a child prescribed pediatric chemotherapy agents?Nausea medicines (antiemetics) may be used to prevent and treat nausea and vomiting. Common medicines used in pediatric cancer patients include: Ondansetron (Zofran®) Granisetron (Kytril®)
Which medication should the nurse be prepared to educate a woman on regarding the management of pregnancy induced nausea and vomiting?Ondansetron (Zofran) (pregnancy category B) is widely used for the treatment of postoperative and chemotherapy-induced nausea and vomiting and is currently one of the most commonly prescribed anti-emetics [157].
|